The role of clinical nonfatal end points in cardiovascular phase II/III clinical trials

Am Heart J. 2000 Apr;139(4):S143-54. doi: 10.1016/s0002-8703(00)90062-0.
No abstract available

MeSH terms

  • Cardiovascular Agents / adverse effects
  • Cardiovascular Agents / therapeutic use*
  • Clinical Trials, Phase II as Topic / statistics & numerical data*
  • Clinical Trials, Phase III as Topic / statistics & numerical data*
  • Humans
  • Reproducibility of Results
  • Survival Analysis
  • Treatment Outcome

Substances

  • Cardiovascular Agents